Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $443 million, representing year-over-year reported growth of 11.5% and organic growth of 3.5% [24][35] - Full year 2024 revenues were $1.61 billion, reflecting 4.5% growth on a reported basis and a decline of 1.3% on an organic basis [29][30] - Adjusted EPS for Q4 was $0.97, up 9% compared to 2023, and adjusted EPS for the full year was $2.56, down 17.4% versus 2023 [25][32] Business Line Data and Key Metrics Changes - In the CSS business, Q4 revenues were $314.7 million, an increase of 15.8% on a reported basis and 4.1% on an organic basis [38] - Tissue Technologies grew 2% on both a reported and organic basis in Q4, with the Wound Reconstruction franchise increasing by 8.2% [42] Market Data and Key Metrics Changes - International sales in CSS were down low single digits due to delayed clearance of shipping holds [41] - The company expanded its international commercial footprint in Brazil, India, Korea, and China, enhancing its global presence [20] Company Strategy and Development Direction - The company is focused on operational excellence, executing a compliance master plan, and enhancing manufacturing capacity [68][69] - There is a commitment to invest in innovation and global expansion while addressing operational challenges [53][54] - The company aims to regain market share and drive growth with differentiated products, particularly in the implant-based breast reconstruction market [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that recent performance has not met expectations and emphasized the need for improvements in quality, manufacturing, and supply chain [11][13] - The company expects Q1 2025 revenues to be between $375 million and $385 million, with organic growth projected to be negative [27][46] - For the full year 2025, revenues are projected to be between $1.65 billion and $1.72 billion, reflecting continued demand for its differentiated portfolio [48] Other Important Information - The company is investing in facility equipment upgrades to enhance quality and capacity, with plans to bring the Braintree facility online in the first half of 2026 [18][22] - The company has established a new standing quality committee to reinforce oversight and accountability [22] Q&A Session Summary Question: Concerns about Integra Skin and shipping holds in 2025 - Management acknowledged the planned maintenance shutdown and lower safety stock levels may prevent meeting demand in Q1, but expects production constraints to diminish throughout the year [61][62] Question: Key strategic initiatives for 2025 - The focus will be on operational excellence, maintaining leadership in core markets, and introducing differentiated new products [68][69] Question: Impact of potential tariffs on manufacturing - The company does not have manufacturing facilities in Mexico or Canada but sources components from those countries and is assessing potential impacts [73][74] Question: Future shipping holds and quality issues - Management indicated that the compliance master plan's assessment phase could lead to potential supply disruptions, although no specific issues are currently known [78][79] Question: Cash flow expectations for 2025 - The company expects operating cash flow and free cash flow to improve in 2025, with a step-up in free cash flow conversion anticipated in Q4 2025 [82][84] Question: Acclarent's growth profile in 2025 - Acclarent is expected to grow at high single digits in 2025, aligning with business expectations and synergies from integration [90][91] Question: Recovery pathway for private label - The private label business is expected to grow at mid-single digit rates, with component supply delays anticipated to be resolved by the second half of 2025 [115][116]

Integra LifeSciences (IART) Q4 2024 Earnings Call February 25, 2025 04:58 PM ET Company Participants Christopher Ward - Senior Director of Investor RelationsMojdeh Poul - President & Chief Executive OfficerLea Knight - Executive Vice President & Chief Financial OfficerMatthew Taylor - Managing DirectorRichard Newitter - Managing DirectorJoanne Wuensch. - Managing DirectorJayson Bedford - Managing Director, Equity Research Conference Call Participants Vik Chopra - AnalystRobert Marcus - AnalystRyan Zimmerman ...

Financial Performance - For the quarter ended December 2024, Integra LifeSciences reported revenue of $442.65 million, reflecting an 11.5% increase year-over-year [1] - EPS for the quarter was $0.97, up from $0.89 in the same quarter last year, resulting in a surprise of +14.12% compared to the consensus estimate of $0.85 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $444.66 million, with a surprise of -0.45% [1] Key Metrics - Organic revenue growth was 3.5%, exceeding the four-analyst average estimate of 2.4% [4] - Revenue from Codman Specialty Surgical totaled $314.66 million, compared to the four-analyst average estimate of $317 million, representing a year-over-year change of +15.8% [4] - Revenue from Tissue Technologies was $127.99 million, slightly above the four-analyst average estimate of $127.54 million, with a year-over-year change of +2.1% [4] - Revenue from Tissue Technologies in Wound Reconstruction and Care was $101.53 million, surpassing the estimated $95.61 million, marking an 8.2% increase year-over-year [4] - Revenue from Tissue Technologies' Private Label was $26.46 million, below the average estimate of $32.20 million, indicating a year-over-year decline of -16.2% [4] Stock Performance - Shares of Integra have returned -16.4% over the past month, contrasting with the Zacks S&P 500 composite's -1.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Integra LifeSciences reported quarterly earnings of $0.97 per share, exceeding the Zacks Consensus Estimate of $0.85 per share, and showing an increase from $0.89 per share a year ago, representing an earnings surprise of 14.12% [1][2] Financial Performance - The company posted revenues of $442.65 million for the quarter ended December 2024, which was 0.45% below the Zacks Consensus Estimate, but an increase from $397.04 million year-over-year [2] - Over the last four quarters, Integra has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Integra shares have declined approximately 2.8% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The current Zacks Rank for Integra is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.54 on revenues of $413.99 million, and for the current fiscal year, it is $2.50 on revenues of $1.71 billion [7] - The estimate revisions trend for Integra is mixed, and changes in these estimates could occur following the recent earnings report [6] Industry Context - The Medical - Instruments industry, to which Integra belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance Princeton, New Jersey, February 25, 2025 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Full-Year 2024 2024 Business Highlights "As I step into my role leading Integra, I am inspired by the strength of our portfolio, the dedication of our team, and the t ...

PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per dil ...

Core Insights - GHO Capital has appointed Jan De Witte as Operating Partner to enhance its portfolio and support transatlantic deal origination [2][6] - Jan De Witte brings extensive experience in leading international growth and transformation in the healthcare and technology sectors [3][4] - GHO Capital aims to leverage Jan's expertise to identify high-growth potential businesses within the healthcare sector [7] Company Overview - GHO Capital Partners LLP is a specialist healthcare investment advisor based in London, focusing on high-growth healthcare opportunities [9] - The firm targets Pan-European and transatlantic internationalization to build market-leading businesses of strategic global value [9] - GHO Capital emphasizes improving healthcare delivery efficiency to enable better, faster, and more accessible healthcare [9] Leadership Background - Jan De Witte previously served as CEO of Integra LifeSciences, where he added $1 billion to the company's total addressable market through strategic acquisitions and innovation [3] - He has also held leadership positions at Barco N.V. and GE Healthcare, focusing on digital transformation and global market expansion [4] - Jan holds an M.B.A. from Harvard Business School and degrees in electromechanical engineering from KU Leuven, Belgium [5]

PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those pl ...

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and es ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to fin ...